Investing.comCodex · 实盘可交易 · 做空市场:美股▲ 赚 +6.91% · 已结算把握 6/10
北京时间·🕒 发布 04:04:31·⟳ 抓取 04:05:03 +32s·⚡ 决策 09-03 04:12:26 +7m23s·54.8 天前
Ultragenyx的Angelman综合征药物apazunersen三期Aspire研究未达主要和关键次要终点
这是后期临床核心读出失败，方向明确为RARE直接利空；美股已收盘，适合以下一交易日开盘做空而非盘后追价。
📄 原文Investing.com↗ 原文
Ultragenyx drug fails phase 3 trial for Angelman syndrome
Wall Street rises on Dell, Nvidia boost and a let up in oil prices, yields NOVATO, Calif. - Ultragenyx Pharmaceutical I…
▲ 赚 +6.91%入场 09-02 盘后首笔 @15.09 → 离场 09-03 常规开盘 @14.00
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(做空:价格在入场线下方)、绿底 = 亏
💡 交易逻辑三期核心读出失败，盘后新鲜利空
怎么做空 开盘做空 不设价格下限（市价成交）
怎么平空 止盈 -8%(半仓)/-15%(清仓) · 止损 +7% · 时间止损 3日
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做空 RARE.US Ultragenyx Pharmaceutical Inc.
建仓日早于近 30 天,只有日线图
成交明细 · 纸面
做空 RARE.US Ultragenyx Pharmaceutical Inc.
| 收益状态 | +6.91% 已平仓 |
|---|---|
| 进场成交 | 2026-09-02 · 盘后首笔 · 09-03 04:08 北京 · @15.09 |
| 离场成交 | 2026-09-03 · 常规开盘 · @14 |
| 毛收益 | +7.22% |
| 成本 | +0.32% |
| 净收益 | +6.91% |
| 计入收益 | +6.91% |
| 计入 | 同日重复,不计入曲线 |
| 建仓日 | 2026-09-02 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 23:47
研究档案
结论摘要
Investing.com在2026-09-02 16:04美东发布称Ultragenyx的apazunersen三期Aspire研究未达主要和关键次要终点，且公司将评估项目去留并削减开支。该项目此前为H2 2026重要读出、已获多项监管资格，失败削弱后期管线价值并增加成本收缩压力；同类小中型生物科技三期失败常出现大幅重定价，因此给RARE.US开盘做空小仓。
消息传播链
- Investing.com称根据新闻稿，RARE的apazunersen三期Aspire研究未达主要和关键次要终点；发布时间为美股收盘后。
- 公司Q2更新曾列明GTX-102三期Aspire已入组129例且H2 2026读出，说明本次为预期中的关键临床读出。
关键理由
- Apazunersen三期Aspire同时未达主要终点和关键次要终点，直接证伪Angelman综合征项目的注册路径。
- 公司此前披露该研究入组129例、H2 2026读出，且GTX-102拥有突破性疗法等资格，失败相对市场预期差明显。
- 商业可及患者约6万人但目前无法转化为近期收入，公司转而评估项目处置和削减费用，短线估值应下修。
主要风险
- RARE仍有GENGLYCOS、UX111等商业化/审批催化，若管理层给出盈利路径或其他管线进展，可能缓冲跌幅。
- 次日若大幅低开超过15%且快速放量承接，追空风险升高，应放弃或只按限价成交。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-01 · 影响 weakens
公司仍强调GENGLYCOS近期获批收入、UX111潜在获批和2027盈利目标，这会缓冲但不推翻GTX-102失败利空。
检索:Ultragenyx Q2 2026 GENGLYCOS UX111 profitability 2027 positive catalysts 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-05-01 · 影响 supports
此前Phase 1/2长期数据和监管资格曾支撑预期，反而放大本次三期失败的预期差；未发现能立即抵消失败的确认性利好。
检索:Ultragenyx GTX-102 Phase 1/2 long term data Breakthrough Therapy Designation 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例确认方向但限制仓位为small，并将入场设为开盘而非无条件追低。
方向:可用先例一致指向负面，但多为analog而非完全对齐样本。
涨幅量级:没有足够8分以上高相似且首发锚干净样本，不能精确定幅；三期失败通常足以支持短线做空。
形态:样本显示主要终点失败常为开盘/首日集中重定价，低开过深后追空的收益风险会恶化。
历史先例(按相似度)
- 相似度 7/10 GOSS.US 2026-02-23 Gossamer Bio三期PAH研究未达主要终点后股价大跌。 原文 ↗
事件后 +1日 -6.0% · +2日 -7.7% · +3日 -15.6% · +4日 -10.7% · +5日 -5.6%
相似度依据:同为美股生物科技三期临床未达主要终点并导致项目路径受损，但适应症和公司现金结构不同。
经验:后期核心读出失败通常带来一次性大幅估值下修。 - 相似度 7/10 MREO.US 2025-12-29 Mereo三期OI研究未达主要终点后股价显著下跌。 原文 ↗
事件后 +1日 +26.6% · +2日 +64.3% · +3日 +84.8% · +4日 +126.4% · +5日 +113.2%
⚠非首发(转载/聚合)·来源层级不符(声明media/实为aggregator) — 该行涨幅别用来定止盈止损
相似度依据:同属罕见病三期失败，且涉及Ultragenyx合作资产相关报道；但标的不是本次RARE单一管线。
经验:罕见病三期失败即使有次要终点亮点，也常难抵消主要终点失败。 - 相似度 6/10 SRPT.US 2025-11-03 Sarepta ESSENCE研究未达主要终点后盘后下跌。 原文 ↗
事件后 +1日 -33.7% · +2日 -23.6% · +3日 -27.9% · +4日 -27.9% · +5日 -29.4%
⚠非首发(转载/聚合)·来源层级不符(声明media/实为aggregator) — 该行涨幅别用来定止盈止损
相似度依据:同为罕见病/遗传病药物三期未达主要终点，但SRPT已有商业化资产和不同疾病背景。
经验:已有收入的生物科技在临床失败后仍会跌，但跌幅可被存量商业化业务缓冲。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,175 字
Wall Street rises on Dell, Nvidia boost and a let up in oil prices, yields
NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced today that its Phase 3 Aspire study for apazunersen in Angelman syndrome did not meet its primary or key secondary endpoints, according to a press release statement.
The study failed to achieve the primary endpoint of change from baseline in Bayley-4 cognitive raw score and the key secondary endpoint of net response in Multidomain Responder Index. The safety profile observed in Aspire was consistent with earlier Phase 1/2 trials.
Apazunersen, also known as GTX-102, is an investigational antisense oligonucleotide therapy delivered via intrathecal administration. The treatment was designed to target and inhibit expression of the UBE3A-AS to reactivate expression of the deficient protein in Angelman syndrome patients.
In the Aspire trial, the randomized groups were comparable at baseline and consistent with patients studied in Phase 2. No differences were observed between the treated and control groups in Bayley Cognition raw scores or in the MDRI when examining net response or mean changes of the individual five endpoints.
The company stated it will evaluate the apazunersen program and make a decision on its disposition. Ultragenyx also plans to assess its operations to implement significant expense reductions while supporting its commercial business.
Angelman syndrome is a rare neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene. The condition affects approximately 60,000 people in commercially accessible geographies and causes cognitive impairment, motor impairment, balance issues and seizures. There are currently no approved therapies for Angelman syndrome.
The company said it will maintain focus on its commercial business, including revenue from the recent approval of GENGLYCOS for glycogen storage disease type Ia and the potential approval of UX111 for Sanfilippo syndrome. Ultragenyx stated it continues toward profitability in 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced today that its Phase 3 Aspire study for apazunersen in Angelman syndrome did not meet its primary or key secondary endpoints, according to a press release statement.
The study failed to achieve the primary endpoint of change from baseline in Bayley-4 cognitive raw score and the key secondary endpoint of net response in Multidomain Responder Index. The safety profile observed in Aspire was consistent with earlier Phase 1/2 trials.
Apazunersen, also known as GTX-102, is an investigational antisense oligonucleotide therapy delivered via intrathecal administration. The treatment was designed to target and inhibit expression of the UBE3A-AS to reactivate expression of the deficient protein in Angelman syndrome patients.
In the Aspire trial, the randomized groups were comparable at baseline and consistent with patients studied in Phase 2. No differences were observed between the treated and control groups in Bayley Cognition raw scores or in the MDRI when examining net response or mean changes of the individual five endpoints.
The company stated it will evaluate the apazunersen program and make a decision on its disposition. Ultragenyx also plans to assess its operations to implement significant expense reductions while supporting its commercial business.
Angelman syndrome is a rare neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene. The condition affects approximately 60,000 people in commercially accessible geographies and causes cognitive impairment, motor impairment, balance issues and seizures. There are currently no approved therapies for Angelman syndrome.
The company said it will maintain focus on its commercial business, including revenue from the recent approval of GENGLYCOS for glycogen storage disease type Ia and the potential approval of UX111 for Sanfilippo syndrome. Ultragenyx stated it continues toward profitability in 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。